{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:06:42Z","timestamp":1793815602215,"version":"4.6.1"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Objective\/Background:<\/jats:title>\n                    <jats:p>The RNPLS-01 trial aimed to evaluate the efficacy and safety of ramucirumab (a VEGFR2 antagonist) combined with nab-paclitaxel, lobaplatin, and S-1 (RNPLS group) versus nab-paclitaxel, lobaplatin, and S-1 alone (NPLS group) in neoadjuvant therapy for advanced gastric cancer (GC), as part of the RNPLS-01 prospective randomized controlled trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis:<\/jats:title>\n                    <jats:p>RNPLS-01 trial enrolled 140 patients with advanced GC across two cohorts (neoadjuvant therapy: n =\u00a070; conversion therapy: n =\u00a070). This report focuses on the neoadjuvant cohort where patients were randomized 1:1 to receive either RNPLS (n\u00a0=\u00a035) or NPLS (n\u00a0=\u00a035). Primary endpoint was pathological complete response (pCR). Secondary endpoints included R0 resection rate, objective response rate (ORR), disease control rate (DCR), and adverse events (AEs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The RNPLS group demonstrated significant improvements in post-operative T stage (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =\u00a00.008), N stage (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =\u00a00.001), and AJCC (American Joint Committee on Cancer) clinical stage (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =\u00a00.003) compared to controls. The RNPLS group demonstrated significantly higher pCR rates compared to the NPLS group (22.9% vs. 2.9%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.0001). The R0 resection rate was 85.7% in the RNPLS group versus 82.9% in the NPLS group. The RNPLS group achieved a significantly higher ORR compared to the NPLS group (68.6% vs. 25.7%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =\u00a00.001), while DCRs were comparable between the two groups (94.3% vs. 77.1%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =\u00a00.055). Treatment-related adverse events (TRAEs) were confined to Grade 1\u20132 severity, with no Grade 3\u20134 events reported in either group. The RNPLS group showed a TRAE incidence of 80.0%, versus 88.6% in the NPLS group (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =\u00a00.324). Neither group exhibited surgical complications during the study period.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Ramucirumab combined with nab-paclitaxel, lobaplatin, and S-1 significantly enhances the pCR rate and ORR in neoadjuvant therapy of locally advanced GC patients, while maintaining an acceptable safety profile.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/js9.0000000000002893","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T15:00:14Z","timestamp":1753196414000},"page":"8060-8069","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Main results of a randomized controlled trial (RNPLS-01): efficacy and safety of ramucirumab combined with nab-paclitaxel, lobaplatin, and S-1 in neoadjuvant therapy for advanced gastric cancer"],"prefix":"10.1097","volume":"111","author":[{"given":"Juan","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Digestive Surgery, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi\u2019an, China"},{"name":"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and National Clinical Research Center for Digestive Diseases, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Digestive Surgery, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunli","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Digestive Surgery, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xisheng","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Digestive Surgery, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shushang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Digestive Surgery, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunsheng","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Digestive Surgery, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengbin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Digestive Surgery, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaobang","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Digestive Surgery, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Digestive Surgery, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiqi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Digestive Surgery, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuewen","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Digestive Surgery, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shisen","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Digestive Surgery, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Digestive Surgery, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangpeng","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Digestive Surgery, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanghui","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Digestive Surgery, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Digestive Surgery, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi\u2019an, China"},{"name":"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and National Clinical Research Center for Digestive Diseases, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2662-0613","authenticated-orcid":false,"given":"Jianyong","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Digestive Surgery, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi\u2019an, China"},{"name":"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and National Clinical Research Center for Digestive Diseases, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Digestive Surgery, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi\u2019an, China"},{"name":"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and National Clinical Research Center for Digestive Diseases, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"R1-20260512","first-page":"209\u201349","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R2-20260512","doi-asserted-by":"crossref","first-page":"393\u2013422","DOI":"10.6004\/jnccn.2023.0019","article-title":"Esophageal and esophagogastric junction cancers, version 2.2023, nccn clinical practice guidelines in oncology","volume":"21","author":"Ajani","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"R3-20260512","first-page":"100082","article-title":"Transparency in the reporting of Artificial Intelligence - the TITAN guideline","volume":"10","author":"Agha","year":"2025","journal-title":"Premier J Sci"},{"key":"R4-20260512","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1186\/s12951-022-01431-8","article-title":"Construction of gastric cancer patient-derived organoids and their utilization in a comparative study of clinically used paclitaxel nanoformulations","volume":"20","author":"Zou","year":"2022","journal-title":"J Nanobiotechnology"},{"key":"R5-20260512","doi-asserted-by":"crossref","first-page":"4438\u201344","DOI":"10.1200\/JCO.2012.48.5805","article-title":"Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial","volume":"31","author":"Hironaka","year":"2013","journal-title":"J Clin Oncol"},{"key":"R6-20260512","doi-asserted-by":"crossref","first-page":"6093","DOI":"10.1038\/s41467-020-19965-6","article-title":"Neoadjuvant FLOT versus SOX phase II randomized clinical trial for patients with locally advanced gastric cancer","volume":"11","author":"Sah","year":"2020","journal-title":"Nat Commun"},{"key":"R7-20260512","first-page":"2261\u201363","article-title":"S-1 and oxaliplatin combined with nanoparticle albumin-bound paclitaxel adjuvant chemotherapy for advanced gastric adenocarcinoma","volume":"135","author":"Xia","year":"2022","journal-title":"Chin Med J (Engl)"},{"key":"R8-20260512","doi-asserted-by":"crossref","first-page":"611\u201325","DOI":"10.1038\/nrm.2016.87","article-title":"Mechanisms and regulation of endothelial VEGF receptor signalling","volume":"17","author":"Simons","year":"2016","journal-title":"Nat Rev Mol Cell Biol"},{"key":"R9-20260512","doi-asserted-by":"crossref","first-page":"2229\u201336","DOI":"10.1158\/1078-0432.CCR-21-3548","article-title":"Phase II study of ramucirumab in advanced biliary tract cancer previously treated by gemcitabine-based chemotherapy","volume":"28","author":"Lee","year":"2022","journal-title":"Clin Cancer Res"},{"key":"R10-20260512","first-page":"1470\u201391","article-title":"Immunotherapy and targeted therapy for advanced gastroesophageal cancer: ASCO guideline","volume":"41","author":"Shah","year":"2023","journal-title":"J Clin Oncol"},{"key":"R11-20260512","doi-asserted-by":"crossref","first-page":"315\u201322","DOI":"10.1007\/s40265-020-01263-6","article-title":"Ramucirumab: a review in hepatocellular carcinoma","volume":"80","author":"Syed","year":"2020","journal-title":"Drugs"},{"key":"R12-20260512","doi-asserted-by":"crossref","first-page":"80\u201390","DOI":"10.1016\/j.pharmthera.2011.03.012","article-title":"Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis","volume":"131","author":"Larsen","year":"2011","journal-title":"Pharmacol Ther"},{"key":"R13-20260512","doi-asserted-by":"crossref","first-page":"1224\u201335","DOI":"10.1016\/S1470-2045(14)70420-6","article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial","volume":"15","author":"Wilke","year":"2014","journal-title":"Lancet Oncol"},{"key":"R14-20260512","doi-asserted-by":"crossref","first-page":"1015\u201324","DOI":"10.1016\/S2468-1253(21)00313-7","article-title":"Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial","volume":"6","author":"Xu","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R15-20260512","doi-asserted-by":"crossref","first-page":"420\u201335","DOI":"10.1016\/S1470-2045(18)30791-5","article-title":"Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Fuchs","year":"2019","journal-title":"Lancet Oncol"},{"key":"R16-20260512","doi-asserted-by":"crossref","first-page":"e198243","DOI":"10.1001\/jamanetworkopen.2019.8243","article-title":"Effect of first-line S-1 plus oxaliplatin with or without ramucirumab followed by paclitaxel plus ramucirumab on advanced Gastric cancer in East Asia: the phase 2 RAINSTORM randomized clinical trial","volume":"2","author":"Yoshikawa","year":"2019","journal-title":"JAMA Network Open"},{"key":"R17-20260512","doi-asserted-by":"crossref","first-page":"106\u201313","DOI":"10.1007\/s10120-017-0745-2","article-title":"Safety, pharmacokinetic, and clinical activity profiles of ramucirumab in combination with three platinum\/fluoropyrimidine doublets in Japanese patients with chemotherapy-na\u00efve metastatic gastric\/gastroesophageal junction cancer","volume":"21","author":"Shitara","year":"2018","journal-title":"Gastric Cancer"},{"key":"R18-20260512","doi-asserted-by":"crossref","first-page":"e29485","DOI":"10.1016\/j.heliyon.2024.e29485","article-title":"Evaluation of the efficacy and safety of ramucirumab combined with nab-paclitaxel, lobaplatin, and S-1 in neoadjuvant and conversion therapy for advanced gastric cancer: a study protocol of prospective single-center, randomized controlled and open label clinical trial (RNPLS-01)","volume":"10","author":"Wang","year":"2024","journal-title":"Heliyon"},{"key":"R20-20260512","doi-asserted-by":"crossref","first-page":"2560\u201365","DOI":"10.1093\/annonc\/mdt238","article-title":"Impact of excision repair cross-complementing gene 1 (ERCC1) on the outcomes of patients with advanced gastric cancer: correlative study in Japan Clinical Oncology Group Trial JCOG9912","volume":"24","author":"Yamada","year":"2013","journal-title":"Ann Oncol"},{"key":"R21-20260512","doi-asserted-by":"crossref","first-page":"215\u201321","DOI":"10.1016\/S1470-2045(08)70035-4","article-title":"S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial","volume":"9","author":"Koizumi","year":"2008","journal-title":"Lancet Oncol"},{"key":"R22-20260512","doi-asserted-by":"crossref","first-page":"1081\u201392","DOI":"10.1016\/S1470-2045(21)00297-7","article-title":"RESOLVE study group. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial","volume":"22","author":"Zhang","year":"2021","journal-title":"Lancet Oncol"},{"key":"R23-20260512","first-page":"3767\u201377","article-title":"Albumin-bound paclitaxel in solid tumors: clinical development and future directions","volume":"9","author":"Kundranda","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"R24-20260512","doi-asserted-by":"crossref","first-page":"81\u201392","DOI":"10.1016\/j.jconrel.2021.12.035","article-title":"SPARC-mediated long-term retention of nab-paclitaxel in pediatric sarcomas","volume":"342","author":"Pascual-Pasto","year":"2022","journal-title":"J Control Release"},{"key":"R25-20260512","doi-asserted-by":"crossref","first-page":"699\u2013712","DOI":"10.1007\/s00280-015-2833-5","article-title":"Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration","volume":"76","author":"Chen","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"R26-20260512","doi-asserted-by":"crossref","first-page":"78\u201394","DOI":"10.1038\/s41568-022-00535-5","article-title":"Targeting DNA damage response pathways in cancer","volume":"23","author":"Groelly","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"R27-20260512","doi-asserted-by":"crossref","first-page":"e2116240","DOI":"10.1001\/jamanetworkopen.2021.16240","article-title":"Effectiveness and safety of apatinib plus chemotherapy as neoadjuvant treatment for locally advanced gastric cancer: a nonrandomized controlled trial","volume":"4","author":"Lin","year":"2021","journal-title":"JAMA Network Open"},{"key":"R28-20260512","doi-asserted-by":"crossref","first-page":"1697\u2013708","DOI":"10.1016\/S1470-2045(16)30531-9","article-title":"Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2\/3 trial","volume":"17","author":"Al-Batran","year":"2016","journal-title":"Lancet Oncol"},{"key":"R29-20260512","doi-asserted-by":"crossref","first-page":"312\u201319","DOI":"10.1016\/S1470-2045(24)00676-4","article-title":"Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): final report of a randomised, open-label, phase 3 trial","volume":"26","author":"Zhang","year":"2025","journal-title":"Lancet Oncol"},{"key":"R30-20260512","doi-asserted-by":"crossref","first-page":"476\u201395","DOI":"10.1038\/s41573-023-00671-z","article-title":"Targeting angiogenesis in oncology, ophthalmology and beyond","volume":"22","author":"Cao","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"R31-20260512","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41392-025-02160-8","article-title":"Perioperative tislelizumab plus chemotherapy for locally advanced gastroesophageal junction adenocarcinoma (NEOSUMMIT-03): a prospective, nonrandomized, open-label, phase 2 trial","volume":"10","author":"Nie","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"R32-20260512","doi-asserted-by":"crossref","first-page":"e003635","DOI":"10.1136\/jitc-2021-003635","article-title":"Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study","volume":"10","author":"Jiang","year":"2022","journal-title":"J Immunother Cancer"},{"key":"R33-20260512","doi-asserted-by":"crossref","first-page":"255\u201365","DOI":"10.1200\/JCO.22.00686","article-title":"Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair\/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase II study","volume":"41","author":"Andr\u00e9","year":"2023","journal-title":"J Clin Oncol"},{"key":"R34-20260512","doi-asserted-by":"crossref","first-page":"30\u201339","DOI":"10.1158\/1078-0432.CCR-22-1366","article-title":"Molecular mechanisms and future implications of VEGF\/VEGFR in cancer therapy","volume":"29","author":"Patel","year":"2023","journal-title":"Clin Cancer Res"},{"key":"R35-20260512","doi-asserted-by":"crossref","first-page":"325\u201340","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"R36-20260512","doi-asserted-by":"crossref","first-page":"58\u201362","DOI":"10.1126\/science.1104819","article-title":"Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy","volume":"307","author":"Jain","year":"2005","journal-title":"Science"},{"key":"R37-20260512","doi-asserted-by":"crossref","first-page":"e1316437","DOI":"10.1080\/2162402X.2017.1316437","article-title":"Arginase inhibition suppresses lung metastasis in the 4T1 breast cancer model independently of the immunomodulatory and anti-metastatic effects of VEGFR-2 blockade","volume":"6","author":"Secondini","year":"2017","journal-title":"Oncoimmunology"},{"key":"R38-20260512","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s11658-024-00682-7","article-title":"Systematic and comprehensive insights into HIF-1 stabilization under normoxic conditions: implications for cellular adaptation and therapeutic strategies in cancer","volume":"30","author":"Zhang","year":"2025","journal-title":"Cell Mol Biol Lett"},{"key":"R39-20260512","first-page":"e70700","article-title":"Hypoxia-inducible factor 1-Alpha (HIF-1\u03b1) and cancer: mechanisms of tumor hypoxia and therapeutic targeting","volume":"16","author":"Basheeruddin","year":"2024","journal-title":"Cureus"},{"key":"R40-20260512","doi-asserted-by":"crossref","first-page":"1131\u201350","DOI":"10.1042\/CS20240537","article-title":"Identifying mitigating strategies for endothelial cell dysfunction and hypertension in response to VEGF receptor inhibitors","volume":"138","author":"Camarda","year":"2024","journal-title":"Clin Sci (Lond)"},{"key":"R41-20260512","doi-asserted-by":"crossref","first-page":"967\u201370","DOI":"10.1093\/annonc\/mdp206","article-title":"Hypertension as a surrogate marker for the activity of anti-VEGF agents","volume":"20","author":"Mir","year":"2009","journal-title":"Ann Oncol"},{"key":"R42-20260512","doi-asserted-by":"crossref","first-page":"153\u201363","DOI":"10.1002\/ijc.34495","article-title":"Perioperative FLOT plus ramucirumab for resectable esophagogastric adenocarcinoma: a randomized phase II\/III trial of the German AIO and Italian GOIM","volume":"153","author":"Goetze","year":"2023","journal-title":"Int J Cancer"}],"container-title":["International Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000002893","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T12:08:48Z","timestamp":1778587728000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000002893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/js9.0000000000002893","relation":{},"ISSN":["1743-9159"],"issn-type":[{"value":"1743-9159","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"2025-04-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}